# GRAIL, Inc.: overview GRAL · Nasdaq · CIK 1699031 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/gral.md) · [Financials](/companies/gral/financials.md) · [Filings](/companies/gral/filings.md) · [Insiders](/companies/gral/insiders.md) Latest reported revenue: [$44.7m](/filings/0001628280-26-054307.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-054307). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [28.7](/filings/0001699031-25-000193.md) | [38.3 d](/filings/0001628280-26-017319.md) | [31.8](/filings/0001628280-26-032090.md) | [35.5](/filings/0001628280-26-054307.md) | [36.2](/filings/0001699031-25-000193.md) | [43.6 d](/filings/0001628280-26-017319.md) | [40.8](/filings/0001628280-26-032090.md) | [44.7](/filings/0001628280-26-054307.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(640.5%)](/filings/0001699031-25-000193.md) | [(358.0%) d](/filings/0001628280-26-017319.md) | [(482.5%)](/filings/0001628280-26-032090.md) | [(446.9%)](/filings/0001628280-26-054307.md) | [(346.2%)](/filings/0001699031-25-000193.md) | [(285.4%) d](/filings/0001628280-26-017319.md) | [(332.9%)](/filings/0001628280-26-032090.md) | [(388.9%)](/filings/0001628280-26-054307.md) | | Net margin | % | [(438.7%)](/filings/0001699031-25-000193.md) | [(253.8%) d](/filings/0001628280-26-017319.md) | [(333.6%)](/filings/0001628280-26-054307.md) | [(320.7%)](/filings/0001628280-26-054307.md) | [(245.8%)](/filings/0001699031-25-000193.md) | [(227.5%) d](/filings/0001628280-26-017319.md) | [(228.5%)](/filings/0001628280-26-054307.md) | [(246.7%)](/filings/0001628280-26-054307.md) | | Diluted EPS | $ per share | [(3.94)](/filings/0001699031-25-000193.md) | not reported | [(3.10)](/filings/0001628280-26-032090.md) | [(3.18)](/filings/0001628280-26-054307.md) | [(2.46)](/filings/0001699031-25-000193.md) | not reported | [(2.29)](/filings/0001628280-26-032090.md) | [(2.56)](/filings/0001628280-26-054307.md) | | Free cash flow | $m | [(106) d](/filings/0001699031-25-000193.md) | [(93.8) d](/filings/0001628280-26-017319.md) | [(95.1)](/filings/0001628280-26-032090.md) | [(77.3) d](/filings/0001628280-26-054307.md) | [(63.6) d](/filings/0001699031-25-000193.md) | [(63.9) d](/filings/0001628280-26-017319.md) | [(87.5)](/filings/0001628280-26-032090.md) | [(81.2) d](/filings/0001628280-26-054307.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2023-01-01) | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $m | [55.6](/filings/0001699031-25-000041.md) | [93.1](/filings/0001628280-26-017319.md) | [126](/filings/0001628280-26-017319.md) | [147](/filings/0001628280-26-017319.md) | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | [(9798.2%)](/filings/0001699031-25-000041.md) | [(1627.6%)](/filings/0001628280-26-017319.md) | [(1743.0%)](/filings/0001628280-26-017319.md) | [(382.0%)](/filings/0001628280-26-017319.md) | | Net margin | % | [(9719.3%)](/filings/0001699031-25-000041.md) | [(1574.2%)](/filings/0001628280-26-017319.md) | [(1613.9%)](/filings/0001628280-26-017319.md) | [(277.5%)](/filings/0001628280-26-017319.md) | | Diluted EPS | $ per share | [(173.89)](/filings/0001699031-25-000041.md) | [(47.21)](/filings/0001628280-26-017319.md) | [(63.54)](/filings/0001628280-26-017319.md) | [(11.11)](/filings/0001628280-26-017319.md) | | Free cash flow | $m | [(584)](/filings/0001699031-25-000041.md) | [(609)](/filings/0001628280-26-017319.md) | [(582)](/filings/0001628280-26-017319.md) | [(300)](/filings/0001628280-26-017319.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/gral/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FARALLON CAPITAL MANAGEMENT, L.L.C.](/funds/909661.md) | 2026-06-30 | $284.1m | 4,161,584 | | Added +907,900 | | [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $275.0m | 4,028,614 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $244.2m | 3,577,075 | | Added +608,539 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $162.9m | 2,385,514 | | Added +493,621 | | [PRIMECAP MANAGEMENT CO/CA/](/funds/763212.md) | 2026-06-30 | $148.8m | 2,180,106 | | Added +336,334 | | [Sessa Capital IM, L.P.](/funds/1595849.md) | 2026-06-30 | $139.1m | 2,037,518 | | Added +318,204 | | [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $125.3m | 1,834,944 | | Added +112,147 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $112.0m | 1,641,117 | | Added +114,012 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $99.8m | 1,462,163 | | Reduced −170,032 | | [Arbiter Partners Capital Management LLC](/funds/1513193.md) | 2026-06-30 | $70.6m | 1,034,297 | | Reduced −300 | ## Recent filings [All 255 filings](/companies/gral/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-06 | 20:11 ET | [10-Q](/filings/0001628280-26-054307.md) | Quarterly report, period 2026-06-30 | 0001628280-26-054307 | | 2026-08-05 | 20:08 ET | [8-K](/filings/0001628280-26-053341.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-053341 | | 2026-06-22 | 20:50 ET | [8-K](/filings/0001628280-26-044693.md) | 5.07 Shareholder vote results | 0001628280-26-044693 | | 2026-06-01 | 20:07 ET | [8-K](/filings/0001628280-26-039461.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-039461 | | 2026-05-07 | 20:09 ET | [10-Q](/filings/0001628280-26-032090.md) | Quarterly report, period 2026-03-31 | 0001628280-26-032090 | | 2026-05-05 | 20:05 ET | [8-K](/filings/0001628280-26-030495.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-030495 | | 2026-04-28 | 20:18 ET | [DEF 14A](/filings/0001628280-26-027946.md) | Proxy statement, period 2026-06-18 | 0001628280-26-027946 | | 2026-03-12 | 20:40 ET | [10-K](/filings/0001628280-26-017319.md) | Annual report, period 2025-12-31 | 0001628280-26-017319 | | 2026-02-19 | 21:18 ET | [8-K](/filings/0001699031-26-000009.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001699031-26-000009 | | 2026-01-12 | 15:30 ET | [8-K](/filings/0001628280-26-001786.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-001786 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-017319.md), filed Mar 12, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/9d218632-302d-4650-b5e1-71a14c84cd3b) ## About the filer - CIK: 1699031 - Tickers: GRAL - Exchange: Nasdaq - SIC code: 8071 Services-Medical Laboratories - State of incorporation: DE - Filer category: Non-accelerated filer
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.